- Home
- DBX vs CORT Comparison
DBX vs CORT Comparison
Compare DBX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBX
- CORT
- Stock Information
- Founded
- DBX 2007
- CORT 1998
- Country
- DBX United States
- CORT United States
- Employees
- DBX N/A
- CORT N/A
- Industry
- DBX Computer Software: Prepackaged Software
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- DBX Technology
- CORT Health Care
- Exchange
- DBX Nasdaq
- CORT Nasdaq
- Market Cap
- DBX 7.7B
- CORT 7.5B
- IPO Year
- DBX 2018
- CORT N/A
- Fundamental
- Price
- DBX $28.00
- CORT $72.27
- Analyst Decision
- DBX Buy
- CORT Strong Buy
- Analyst Count
- DBX 4
- CORT 4
- Target Price
- DBX $31.00
- CORT $142.00
- AVG Volume (30 Days)
- DBX 3.8M
- CORT 1.6M
- Earning Date
- DBX 08-07-2025
- CORT 07-28-2025
- Dividend Yield
- DBX N/A
- CORT N/A
- EPS Growth
- DBX 1.18
- CORT 8.36
- EPS
- DBX 1.48
- CORT 1.14
- Revenue
- DBX $2,541,600,000.00
- CORT $685,446,000.00
- Revenue This Year
- DBX N/A
- CORT $35.83
- Revenue Next Year
- DBX N/A
- CORT $35.24
- P/E Ratio
- DBX $18.86
- CORT $63.26
- Revenue Growth
- DBX 0.79
- CORT 30.93
- 52 Week Low
- DBX $21.32
- CORT $29.42
- 52 Week High
- DBX $33.33
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- DBX 41.80
- CORT 49.68
- Support Level
- DBX $27.28
- CORT $68.52
- Resistance Level
- DBX $28.70
- CORT $75.95
- Average True Range (ATR)
- DBX 0.60
- CORT 2.66
- MACD
- DBX -0.12
- CORT -0.13
- Stochastic Oscillator
- DBX 25.55
- CORT 42.13
About DBX Dropbox Inc.
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.